Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Whitehawk Therapeutics (WHWK) Net Margin (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Net Margin for 7 consecutive years, with 201.92% as the latest value for Q1 2025.

  • On a quarterly basis, Net Margin rose 13972.0% to 201.92% in Q1 2025 year-over-year; TTM through Sep 2025 was 717.23%, a 47118.0% decrease, with the full-year FY2024 number at 245.13%, up 2491.0% from a year prior.
  • Net Margin was 201.92% for Q1 2025 at Whitehawk Therapeutics, up from 252.42% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 1941.82% in Q2 2021 to a low of 3701.45% in Q1 2021.
  • A 5-year average of 368.69% and a median of 262.82% in 2022 define the central range for Net Margin.
  • Biggest YoY gain for Net Margin was 310080bps in 2022; the steepest drop was -247336bps in 2022.
  • Whitehawk Therapeutics' Net Margin stood at 114.21% in 2021, then tumbled by -133bps to 266.18% in 2022, then rose by 3bps to 257.18% in 2023, then rose by 2bps to 252.42% in 2024, then grew by 20bps to 201.92% in 2025.
  • Per Business Quant, the three most recent readings for WHWK's Net Margin are 201.92% (Q1 2025), 252.42% (Q4 2024), and 173.95% (Q3 2024).